Published: 30 March 2022
Author(s): Marco Lanzillotta, Matteo Tacelli, Massimo Falconi, Paolo Giorgio Arcidiacono, Gabriele Capurso, Emanuel Della-Torre
Issue: June 2022
Section: Original article

Autoimmune pancreatitis (AIP) is a rare form of chronic pancreatitis that can lead to end-stage organ damage if left untreated [1]. To date, at least two different subtypes of AIP have been identified, namely type 1/IgG4-related lymphoplasmacytic sclerosing pancreatitis and type 2/ idiopathic duct-centric pancreatitis [2]. Despite established differences in terms of epidemiology, clinical presentation, histological features, and relapse rate, type 1 and type 2 AIP share a predictable response to glucocorticoid (GC) therapy [3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.